CLA: definitive absence of insulin resistance promotion in Scandinavians

Anthony Almada, CEO

February 28, 2007

1 Min Read
New Hope logo in a gray background | New Hope

This month's study, "CLA: definitive absence of insulin resistance promotion in Scandinavians," sought to assess the impact of long-term CLA supplementation upon whole body insulin resistance in a subset of overweight-obese subjects, employing a rigorous measure of insulin resistance.

Click here for pdf.

About the Author

Anthony Almada

CEO, Vitargo Global Sciences

Anthony L. Almada, MSc, FISSN, has collaborated on more than 50 university-based human studies assessing sports nutrition products. He was the co-founder of EAS (which introduced creatine to North America in 1993) and is the CEO of Vitargo Global Sciences Inc.

Subscribe and receive the latest updates on trends, data, events and more.
Join 57,000+ members of the natural products community.

You May Also Like